Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Last Updated: November 14, 2017; Last Reviewed: November 14, 2017
|Abrams, Elaine J.||M||ViiV||Advisory Board|
|Best, Brookie M.||M||PPD||DSMB
|C&R Research, Inc.||DSMB|
|Cohn, Susan E.
||M||Eli Lilly and Company
||M||AIDS Malignancy Consortium||DSMB|
|Flynn, Patricia M.||M||Merck
|Kourtis, Athena, P.||HHS||None||N/A|
|Lazenby, Gweneth B.
|Maupin, Robert T.
|Mofenson, Lynne M.
|Prioleau, Fatima Y.||M||None||N/A|
|Siberry, George K.||ES||None||N/A|
|Spector, Stephen A.||M||None||N/A|
|Squires, Kathleen E.
||M||Bristol Myers Squibb||Advisory Board|
|Eli Lilly and Company||Stockholder|
|Watts, D. Heather||HHS||None||N/A|
|Key to Acronyms: DSMB = Data Safety Monitoring Board; CC = Panel Co-Chairs; ES = Executive Secretary; ExOM = Ex Officio Member; HHS = Member from Department of Health and Human Services; M = Member; N/A = Not applicable; NVO = Nonvoting Observer|